You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 1, 2024

Claims for Patent: 10,973,806

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,973,806

Title:	Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin
Abstract:	The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.
Inventor(s):	Desai; Neil P. (Pacific Palisades, CA)
Assignee:	Abraxis BioScience, LLC (Summit, NJ)
Application Number:	15/737,936
Patent Claims:	1. A method of treating a malignant perivascular epithelioid cell tumor (PEComa) in an individual, comprising intravenously administering to the individual an effective amount of a composition comprising nanoparticles comprising sirolimus and an albumin, wherein the effective amount of sirolimus in the nanoparticle composition is about 56 mg/m.sup.2 to about 100 mg/m.sup.2, and wherein the nanoparticle composition is administered on days 1 and 8 of a 21-day cycle. 2. The method of claim 1, wherein the PEComa is selected from the group consisting of a pulmonary clear cell `sugar` tumor, and a PEComa not otherwise specified (PEComa-NOS). 3. The method of claim 1, wherein the PEComa is locally advanced, metastatic, or recurrent. 4. The method of claim 1, wherein the nanoparticles in the composition have an average diameter of no greater than about 150 nm. 5. The method of claim 1, wherein sirolimus in the nanoparticles is coated with the albumin. 6. The method of claim 1, wherein the weight ratio of albumin and sirolimus in the nanoparticle composition is about 1:1 to about 9:1. 7. The method of claim 1, wherein the albumin is human albumin. 8. The method of claim 7, wherein the albumin is human serum albumin. 9. The method of claim 1, wherein the individual is human. 10. The method of claim 1, wherein the effective amount of sirolimus in the nanoparticle composition is about 100 mg/m.sup.2. 11. The method of claim 1, wherein the effective amount of sirolimus in the nanoparticle composition is about 75 mg/m.sup.2. 12. The method of claim 1, wherein the effective amount of sirolimus in the nanoparticle composition is about 56 mg/m.sup.2.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.